• Investment World
• eWorld
• Brand Line
• Mentor
• Life
• Canvas
• Praxis
• Urban Pulse
• Brand Quest
• The New Manager

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Cross Currency

• Rates
  
  

Shipping

• Ports
  
  

Archives

• Yesterday
• Datewise
• Resources
• In Focus
• In Depth

Group Sites

• The Hindu
• The Hindu ePaper
• Business Line
• Business Line ePaper
• Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

Our Bureau

Hyderabad, June 26

Hyderabad-based Natco Pharma Ltd has secured approval from the US Food and Drug Administration for its abbreviated new drug for Ondansetron Hydrochloride tablets in multiple strengths (4 mg and 8 mg).

It has already shipped out the first consignment of these tablets meant for distribution in the US through its marketing partners. Ondansetron Hydrochloride is a popular anti-emetic, commonly used by cancer patients. The market for Ondansetron generics, all over the US is expected to be in the region of around $1.5 billion.

More Stories on : Regulatory Bodies & Rulings | Pharmaceuticals

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
TCS to provide solution for Ferrari's F1 cars

Copyright © 2007, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line